INTERNATIONAL JOURNAL OF MEDICINE AND PHARMACY最新文献

{"title":"The �BETTER TEACHER� mnemonic: A Practical Guide for Busy Community-Based Clinical Teachers","authors":"Michael Ward","doi":"10.15640/ijmp.v7n2a2","DOIUrl":"https://doi.org/10.15640/ijmp.v7n2a2","url":null,"abstract":"The continued success and growth of distributed medical education into geographically dispersed communities has resulted in a dramatic increase in the number of community-based clinician teachers. We have created a simple mnemonic to help capture, translate and review classic and contemporary teaching concepts for the busy community preceptor. The ―BETTER TEACHER‖ guide was designed to provide practical teaching tips for busy clinicians, and to act as a resource for those teachers looking to expand their own understanding of current concepts in medical education. Although presented from a Family Medicine teaching perspective, the fundamental concepts discussed here can be applied widely to include training in various Allied Health programs and beyond.","PeriodicalId":422929,"journal":{"name":"INTERNATIONAL JOURNAL OF MEDICINE AND PHARMACY","volume":"80 1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130865854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Risks versus Benefits with Concomitant Use of Budesonide Nebulizers and Systemic Corticosteroids in COPD Exacerbations","authors":"J. B. Hill, Jon P. Wietholter","doi":"10.15640/ijmp.v7n2a1","DOIUrl":"https://doi.org/10.15640/ijmp.v7n2a1","url":null,"abstract":": Background: Systemic corticosteroids are recommended for treatment of chronic obstructive pulmonary disease (COPD) exacerbations. Studies suggest nebulized budesonide may beequivalent to systemic corticosteroids in COPD exacerbations. However, there is limited data on benefits or risks of concomitant nebulized and systemic corticosteroid use during COPD exacerbations. Methods: This was a single-center, retrospective study evaluating subjects admitted with a COPD exacerbation who received systemic corticosteroids with or without nebulized budesonide. Subjects were included if they had a COPD exacerbation, received systemic corticosteroids of at least 40 mg prednisone equivalents daily for at least 48 hours, and received nebulized budesonide for at least 48 hours if in the budesonide arm. Exclusion criteria included subjects with asthma, active cancer or other forms of immunosuppression, recent systemic corticosteroid usage, or active fungal infection(s). The primary outcome was to compare length of stay between treatment groups. Secondary outcomes were to compare adverse effect rates. Results: 645 subject charts were reviewed and 75 subjects were included(n=41 in the budesonide group; n=34 in the non-budesonide group). Length of stay averaged 4.63 and 3.62 days (p = 0.18) in the budesonide and non-budesonide arms, respectively. Hyperglycemic events occurred significantly more often in the budesonide group (n=164 vs. 92 (p = 0.02)) while thrush diagnoses were not significantly different (n=4 vs. 0 (p = 0.12)). Conclusion: Nebulized budesonide in addition to systemic corticosteroids during a COPD exacerbation does not decrease hospital length of stay and significantly increases the risk of hyperglycemic events. A Other shown that nebulized budesonide appears to be equivalent to systemic corticosteroids as and prednisone in improving pulmonary function, forced expiratory volume in 1 second (FEV saturation of peripheral oxygen (SpO 2 ),in reducing symptoms, and treating COPD exacerbations. Recent practice trends within certain institutions have included utilizing nebulized budesonide in addition to systemic corticosteroids during a COPD exacerbation. Currently, only one study has evaluated this particular corticosteroid combination therapy and showed that hospital length of stay was longer in patients receiving both systemic and corticosteroids.","PeriodicalId":422929,"journal":{"name":"INTERNATIONAL JOURNAL OF MEDICINE AND PHARMACY","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132265068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychosocial Impact of COVID 19 Pandemic on Healthcare Workers in Selected Hospitals in Khartoum State, Khartoum, Sudan, 2020","authors":"Zeinab Ibrahim Swar Eldahab, Mohamed Al Seiddig, Gaffar Alemam,Mohammed Ishag","doi":"10.15640/ijmp.v9n1a5","DOIUrl":"https://doi.org/10.15640/ijmp.v9n1a5","url":null,"abstract":"","PeriodicalId":422929,"journal":{"name":"INTERNATIONAL JOURNAL OF MEDICINE AND PHARMACY","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125653387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subclinical Hyperthyroidism, an Under-Recognized Entity","authors":"S. Igala, M. Machado, B. Neugaard, P. Foulis, J. Gomez-Daspet","doi":"10.15640/IJMP.V7N1A1","DOIUrl":"https://doi.org/10.15640/IJMP.V7N1A1","url":null,"abstract":"Purpose: Determine the medical evaluation completed and the clinical progression observed in subjects with Endogenous Subclinical Hyperthyroidism (ESCH).Method: This is a single site retrospective chart review of subjects who visited the Ambulatory Care Clinics at the James A. Haley VA Hospital (JAHVA), Tampa, Florida. Subjects were selected and charts reviewed using the automatic data mining tool. Inclusion criteria encompassed subjects’ low thyroid stimulating hormone (TSH) and normal T4 and T3 levels.Results: 95 subjects met criteria for inclusion. At the end of one year, 48 (51%) had normal thyroid function tests (TFTs), 43 (45%) had persistent ESCH and 4 (4%) had overt hyperthyroidism. A radioiodine thyroid uptake/scan was completed in 32 (33%) subjects. Only 9 (10%) had thyroid stimulating Immunoglobulin (TSI) or anti-thyroid peroxidase antibody (anti-TPO) studies. A bone density study was not completed. Conclusions: Out of the 95 subjects with ESCH, at the end of one year 51% had normal TFTs, 45% had persistent ESCH and 4% had hyperthyroidism. Less than 50% of the subjects received further tests. It is recommended that subjects with ESCH be followed periodically with TFTs and further evaluation may be required to assess cause, severity, risk of complications and need for treatment.","PeriodicalId":422929,"journal":{"name":"INTERNATIONAL JOURNAL OF MEDICINE AND PHARMACY","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125942937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}